Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-01-12

Clinical Trial Update: Study of Ravulizumab in Pediatric Participants With HSCT-TMA [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Ravulizumab in pediatric participants with hematopoietic stem cell transplantation-associated thrombotic microangiopathy has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ULTOMIRIS (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Thrombotic Microangiopathy | Phase 3 | Status: COMPLETED | Results posted: 2026-01-12